Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.9800
- TODAY'S CHANGE (%)-1.4400 (-3.5626%)
- Bid / Lots36.4100/ 1
- Ask / Lots44.6000/ 1
- Open / Previous Close40.3500 / 40.4200
- Day Range
- 52 Week Range
- Volume359,807
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1035 | 40.35 |
| 09:34 ET | 400 | 40.38 |
| 09:45 ET | 500 | 40.66 |
| 09:50 ET | 400 | 40.605 |
| 09:57 ET | 282 | 40.53 |
| 09:59 ET | 100 | 40.51 |
| 10:01 ET | 280 | 40.54 |
| 10:03 ET | 303 | 40.47 |
| 10:06 ET | 600 | 40.505 |
| 10:08 ET | 200 | 40.41 |
| 10:10 ET | 100 | 40.3 |
| 10:14 ET | 100 | 40.45 |
| 10:15 ET | 505 | 40.41 |
| 10:26 ET | 100 | 40.33 |
| 10:28 ET | 100 | 40.47 |
| 10:32 ET | 228 | 40.411 |
| 10:42 ET | 100 | 40.4 |
| 10:44 ET | 700 | 40.32 |
| 10:48 ET | 400 | 40.22 |
| 10:55 ET | 403 | 40.23 |
| 10:57 ET | 100 | 40.23 |
| 11:00 ET | 993 | 40.27 |
| 11:02 ET | 700 | 40.36 |
| 11:04 ET | 700 | 40.27 |
| 11:06 ET | 1220 | 40.12 |
| 11:09 ET | 100 | 40.16 |
| 11:11 ET | 1200 | 40.08 |
| 11:22 ET | 1512 | 39.99 |
| 11:24 ET | 1400 | 39.9 |
| 11:27 ET | 200 | 39.88 |
| 11:29 ET | 100 | 39.935 |
| 11:36 ET | 3147 | 39.915 |
| 11:38 ET | 100 | 40.02 |
| 11:42 ET | 200 | 39.93 |
| 11:44 ET | 300 | 39.91 |
| 11:45 ET | 108 | 39.96 |
| 11:49 ET | 300 | 39.8 |
| 11:54 ET | 100 | 39.95 |
| 11:56 ET | 100 | 39.96 |
| 12:05 ET | 400 | 39.91 |
| 12:07 ET | 600 | 39.83 |
| 12:09 ET | 541 | 39.85 |
| 12:12 ET | 5100 | 39.92 |
| 12:16 ET | 500 | 39.86 |
| 12:18 ET | 1617 | 40.06 |
| 12:20 ET | 100 | 39.94 |
| 12:23 ET | 1139 | 39.91 |
| 12:27 ET | 175 | 39.8821 |
| 12:32 ET | 400 | 40.03 |
| 12:38 ET | 100 | 40.03 |
| 12:45 ET | 200 | 40.01 |
| 12:54 ET | 500 | 39.93 |
| 12:57 ET | 2150 | 39.8 |
| 12:59 ET | 334 | 39.86 |
| 01:01 ET | 600 | 39.8 |
| 01:06 ET | 30440 | 39.71 |
| 01:10 ET | 1100 | 39.62 |
| 01:12 ET | 300 | 39.57 |
| 01:14 ET | 100 | 39.545 |
| 01:19 ET | 200 | 39.47 |
| 01:21 ET | 100 | 39.465 |
| 01:28 ET | 200 | 39.47 |
| 01:32 ET | 2056 | 39.425 |
| 01:33 ET | 300 | 39.39 |
| 01:35 ET | 700 | 39.42 |
| 01:37 ET | 100 | 39.42 |
| 01:42 ET | 100 | 39.44 |
| 01:44 ET | 1704 | 39.551 |
| 01:46 ET | 100 | 39.565 |
| 01:48 ET | 500 | 39.505 |
| 01:55 ET | 100 | 39.535 |
| 01:57 ET | 100 | 39.52 |
| 02:00 ET | 40890 | 39.55 |
| 02:02 ET | 17752 | 39.48 |
| 02:04 ET | 2100 | 39.72 |
| 02:06 ET | 200 | 39.735 |
| 02:08 ET | 2600 | 39.74 |
| 02:09 ET | 557 | 39.68 |
| 02:15 ET | 100 | 39.655 |
| 02:18 ET | 100 | 39.655 |
| 02:20 ET | 700 | 39.55 |
| 02:22 ET | 300 | 39.53 |
| 02:24 ET | 24592 | 39.49 |
| 02:27 ET | 100 | 39.53 |
| 02:31 ET | 207 | 39.505 |
| 02:33 ET | 100 | 39.5325 |
| 02:36 ET | 300 | 39.535 |
| 02:38 ET | 1757 | 39.34 |
| 02:40 ET | 12869 | 39.41 |
| 02:42 ET | 10800 | 39.34 |
| 02:44 ET | 200 | 39.365 |
| 02:45 ET | 1893 | 39.365 |
| 02:47 ET | 500 | 39.365 |
| 02:49 ET | 200 | 39.35 |
| 02:51 ET | 1656 | 39.25 |
| 02:54 ET | 200 | 39.24 |
| 02:56 ET | 300 | 39.275 |
| 02:58 ET | 100 | 39.24 |
| 03:00 ET | 300 | 39.22 |
| 03:02 ET | 100 | 39.295 |
| 03:03 ET | 1126 | 39.31 |
| 03:05 ET | 100 | 39.325 |
| 03:12 ET | 407 | 39.27 |
| 03:14 ET | 992 | 39.22 |
| 03:18 ET | 2774 | 39.08 |
| 03:20 ET | 900 | 38.98 |
| 03:23 ET | 100 | 38.94 |
| 03:25 ET | 200 | 38.985 |
| 03:27 ET | 1301 | 38.89 |
| 03:30 ET | 700 | 38.89 |
| 03:32 ET | 100 | 38.905 |
| 03:34 ET | 697 | 38.84 |
| 03:36 ET | 200 | 38.85 |
| 03:38 ET | 500 | 38.835 |
| 03:39 ET | 1100 | 38.88 |
| 03:41 ET | 1008 | 38.97 |
| 03:43 ET | 900 | 38.9 |
| 03:45 ET | 500 | 38.93 |
| 03:48 ET | 883 | 38.885 |
| 03:50 ET | 4033 | 38.83 |
| 03:52 ET | 2338 | 39.015 |
| 03:54 ET | 3557 | 38.94 |
| 03:56 ET | 1900 | 38.92 |
| 03:57 ET | 5086 | 38.845 |
| 03:59 ET | 3736 | 38.98 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -14.4x | --- |
Apogee Therapeutics Inc | 3.1B | -24.1x | --- |
Dyne Therapeutics Inc | 3.1B | -8.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.4x | --- |
Summit Therapeutics Inc | 3.2B | -26.5x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
